Von Willebrand disease in the United States: A perspective from Wisconsin

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 5, 2011, Pages 528-534

  Flood, Veronica H ^a,b   Gill, Joan Cox ^a,b,c   Friedman, Kenneth D ^c   Bellissimo, Daniel B ^c   Haberichter, Sandra L ^c   Montgomery, Robert R ^a,b,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Children's Hospital of Wisconsin   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

bleeding disorders; Von Willebrand disease; von Willebrand factor

Indexed keywords

AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; DESMOPRESSIN; DESMOPRESSIN ACETATE; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

AFRICAN AMERICAN; BLEEDING; DIAGNOSTIC TEST; DNA POLYMORPHISM; GENERAL PRACTITIONER; GENETIC VARIABILITY; HEALTH PROGRAM; HEMATOLOGY; HUMAN; LABORATORY TEST; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NATIONAL HEALTH ORGANIZATION; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; UNITED STATES; VON WILLEBRAND DISEASE;

FEMALE; HUMANS; MALE; MUTATION; NATIONAL INSTITUTES OF HEALTH (U.S.); PRACTICE GUIDELINES AS TOPIC; UNITED STATES; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; WISCONSIN;

EID: 81755171917     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1281039     Document Type: Review

References (31)

1. Werner E J., Broxson E H., Tucker E L., Giroux D S., Shults J, Abshire T C. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993 123 6 893-898 (Pubitemid 23353251)
2. Sadler J E., Mannucci P M., Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000 84 2 160-174 (Pubitemid 30601459)
3. Weiss H J., Ball A P., Mannucci P M. Incidence of severe von Willebrand's disease. N Engl J Med 1982 307 2 127
4. Sadler J E., Budde U, Eikenboom J C. et al, Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006 4 10 2103-2114 (Pubitemid 44403432)
5. Soucie J M., Cianfrini C, Janco R L. et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004 103 7 2467-2473 (Pubitemid 38392995)
6. Centers for Disease Control and Prevention. Universal Data Collection Project. Available at: www.cdc.gov/ncbddd/blooddisorders/udc/index.html Accessed December 9, 2010
7. O'Brien L A., James P D., Othman M et al, Association of Hemophilia Clinic Directors of Canada. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood 2003 102 2 549-557 (Pubitemid 36841974)
8. Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006 4 4 766-773
9. Flood V H., Gill J C., Morateck P A. et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010 116 2 280-286
10. Friedman K D., Bellissimo D B., Christopherson P A. et al. Fourteen percent of healthy African Americans participating in the Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB-VWD) are heterozygous for the VWF gene mutation H817Q associated with type 2N von Willebrand disease. Blood 2010 116 21 239 (Abst)
11. Nichols W L., Hultin M B., James A H. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008 14 2 171-232 (Pubitemid 351343618)
12. James A H., Manco-Johnson M J., Yawn B P., Dietrich J E., Nichols W L. von Willebrand disease: key points from the 2008 National Heart, Lung, and Blood Institute guidelines. Obstet Gynecol 2009 114 3 674-678
13. Gill J C., Endres-Brooks J, Bauer P J., Marks W J. Jr, Montgomery R R. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987 69 6 1691-1695 (Pubitemid 17091627)
14. Adcock D M., Bethel M, Valcour A. Diagnosing von Willebrand disease: a large reference laboratory's perspective. Semin Thromb Hemost 2006 32 5 472-479 (Pubitemid 44157384)
15. Favaloro E J. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007 33 8 727-744 (Pubitemid 351158442)
16. Ribba A S., Loisel I, Lavergne J M. et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 2001 86 3 848-854 (Pubitemid 32834196)
17. Riddell A F., Gomez K, Millar C M. et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood 2009 114 16 3489-3496
18. Flood V H., Lederman C A., Wren J S. et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost 2010 8 6 1431-1433
19. Goodeve A, Eikenboom J, Castaman G et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007 109 1 112-121 (Pubitemid 46053051)
20. James P D., Notley C, Hegadorn C et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007 109 1 145-154 (Pubitemid 46053055)
21. Favaloro E J. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost 2008 34 1 113-127
22. Sadler J E., Ginsburg D, Consortium on von Willebrand Factor Mutations and Polymorphisms and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. A database of polymorphisms in the von Willebrand factor gene and pseudogene. Thromb Haemost 1993 69 2 185-191 (Pubitemid 23041191)
23. International Society on Thrombosis and Haemostasis Scientific and Standardization Committee. ISTH-SSC VWF Online Database. Available at: http://www.vwf.group.shef.ac.uk Accessed December 21, 2010
24. Federici A B., Mannucci P M., Castaman G et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009 113 3 526-534
25. Haberichter S L., Balistreri M, Christopherson P et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006 108 10 3344-3351
26. Haberichter S L., Castaman G, Budde U et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008 111 10 4979-4985
27. Bailey A G., McNaull P P., Jooste E, Tuchman J B. Perioperative crystalloid and colloid fluid management in children: where are we and how did we get here? Anesth Analg 2010 110 2 375-390
28. Jiménez-Yuste V, Prim M P., De Diego J I. et al. Otolaryngologic surgery in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 2002 128 12 1365-1368 (Pubitemid 35424666)
29. Olowokure O, Fishman M, Cromwell C, Aledort L. DDAVP for von Willebrand menorrhagiasevere hyponatraemia, haemolysis, seizure, coma!! Caution. Haemophilia 2009 15 3 837
30. Berntorp E, Abshire T, Federici A B. Regular replacement therapy as prophylaxis in severe forms of von Willebrand disease: Initial results from the von Willebrand Disease Prophylaxis Network (VWD PN) Study Group. Blood 2010 116 21 236 (Abst)
31. Rivard G E., Aledort L, Alphanate Surgical Investigators. Efficacy of factor VIII/ von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia 2008 14 2 271-275 (Pubitemid 351338686)